Virios Therapeutics terminates at-the-market sales agreement

Virios Therapeutics provided notice of termination of the Capital on Demand Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023. The Company has initiated the 10-day termination process under the Sales Agreement, with the official termination taking effect on September 28, 2023. The Company will make no sales under the Sales Agreement during this period. The Company’s management team is currently focusing its attention on short-to-medium term operational priorities that are within the current operating budget, including: Providing an additional grant to conduct a second Long-COVID study with the Bateman Horne Center. This new study is planned as a double-blinded, placebo-controlled assessment of IMC-2 in Long-COVID. Exploring opportunities for non-dilutive funding to support further IMC-2 development. Preparing for a Pre-Investigational New Drug meeting with the Food & Drug Administration to discuss IMC-2 as a potential treatment for Long-COVID and other fatigue related disorders. Prosecuting a patent application covering the treatment of Long-COVID and Alzheimer’s disease with combination antiviral formulations. Exploration of potential partnerships for both the fibromyalgia and Long-COVID Programs.